PMID- 27035791
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20181202
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 35
IP  - 6
DP  - 2016 Jun
TI  - Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and 
      COX-2 expression in breast cancer cells.
PG  - 3248-56
LID - 10.3892/or.2016.4716 [doi]
AB  - Gold nanoparticles (AuNPs) with antitumorigenic effects obstruct the initiation, 
      development and progression of tumors via the regulation of various processes, 
      such as proliferation and apoptosis. However, the effects of AuNPs on breast 
      cancer metastasis have not been well studied, and their response to 
      12-O-tetradecanoylphorbol-13-acetate (TPA) stimulation remains unclear. 
      Therefore, we synthesized resveratrol-capped gold nanoparticles (Rev-AuNPs) using 
      green nanotechnology and investigated their potential anti-invasive properties in 
      human breast cancer cells in response to TPA stimulation. The Rev-AuNPs formed 
      spherical nanoparticles of 22.28+/-2.98 nm in diameter. Next, we found that 
      non-cytotoxic concentrations of Rev-AuNPs significantly suppressed the 
      TPA-induced migration and invasion abilities of breast cancer cells. Rev-AuNPs 
      suppressed TPA-induced enzymatic activity and the expression of matrix 
      metalloproteinase (MMP)-9 and cyclooxygenase-2 (COX-2). Furthermore, Rev-AuNP 
      treatment remarkably downregulated TPA-induced nuclear translocation and 
      transcriptional activation of nuclear transcription factor-kappaB (NF-kappaB) and 
      activator protein-1 (AP-1). Rev-AuNPs reduced the phosphorylation of 
      phosphoinositide 3-kinase/Akt (PI3K/Akt) and extracellular signal-regulated 
      kinase (ERK)1/2 signaling, but did not affect the phosphorylation of Jun 
      N-terminal kinase (JNK) or p38 MAPK in the TPA-stimulated breast cancer cells. 
      Notably, Rev-AuNPs generally showed better anti-invasive activity than 
      resveratrol without cytotoxicity. The inhibitory effect of Rev-AuNPs on MMP-9, 
      COX-2, NF-kappaB, AP-1, PI3K/Akt and ERK activation was stronger than that of 
      resveratrol for the same concentrations. We also demonstrated that Rev-AuNPs 
      induced heme oxygenase-1 (HO-1) expression and that the inhibition of MMP-9 and 
      COX-2 expression and MMP-9 enzymatic activity of Rev-AuNPs were abrogated by 
      siRNA knockdown of HO-1 expression. Our findings revealed that the anti-invasive 
      effects of Rev-AuNPs in response to TPA-stimulation were mediated by the 
      suppression of MMP-9, COX-2, NF-kappaB, AP-1, PI3K/Akt and ERK and/or the activation 
      of HO-1 signaling cascades. This novel finding emphasizes the pharmacological 
      ability of Rev-AuNPs to treat breast cancer metastasis.
FAU - Park, Sun Young
AU  - Park SY
AD  - Bio-IT Fusion Technology Research Institute, Pusan National University, 
      Busan 609-735, Republic of Korea.
FAU - Chae, Seon Yeong
AU  - Chae SY
AD  - Department of Nano Fusion Technology, Graduate School, Pusan National University, 
      Busan 609-735, Republic of Korea.
FAU - Park, Jin Oh
AU  - Park JO
AD  - Department of Nano Fusion Technology, Graduate School, Pusan National University, 
      Busan 609-735, Republic of Korea.
FAU - Lee, Kyu Jin
AU  - Lee KJ
AD  - Department of Nano Fusion Technology, Graduate School, Pusan National University, 
      Busan 609-735, Republic of Korea.
FAU - Park, Geuntae
AU  - Park G
AD  - Department of Nano Fusion Technology, Graduate School, Pusan National University, 
      Busan 609-735, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20160329
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Nanoconjugates)
RN  - 0 (Stilbenes)
RN  - 7440-57-5 (Gold)
RN  - EC 1.14.14.18 (HMOX1 protein, human)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Cell Movement/drug effects
MH  - Cyclooxygenase 2/*metabolism
MH  - Enzyme Activation
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Gold/*pharmacology
MH  - Heme Oxygenase-1/metabolism
MH  - Humans
MH  - MCF-7 Cells
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - *Nanoconjugates
MH  - Neoplasm Invasiveness
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
EDAT- 2016/04/02 06:00
MHDA- 2017/03/18 06:00
CRDT- 2016/04/02 06:00
PHST- 2015/12/04 00:00 [received]
PHST- 2016/01/26 00:00 [accepted]
PHST- 2016/04/02 06:00 [entrez]
PHST- 2016/04/02 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
AID - 10.3892/or.2016.4716 [doi]
PST - ppublish
SO  - Oncol Rep. 2016 Jun;35(6):3248-56. doi: 10.3892/or.2016.4716. Epub 2016 Mar 29.